Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.36 |
| ▸ | TDP2 | O95551 | 2/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862741 | 0.85 | HTR2C (0.39) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL25101414 | 0.80 | MLYCD (0.37) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL436752 | 0.78 | ALDH1A1 (0.48) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL17603822 | 0.77 | ALDH1A1 (0.42) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL21057516 | 0.76 | ALDH1A1 (0.44) | ALDH1A1CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL17603690 | 0.73 | LMNA (0.42) | ALDH1A1MEN1MAPTKMT2AHPGD | |
| SCHEMBL17256500 | 0.73 | SMURF1 (0.48) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL9116428 | 0.73 | ALDH1A1 (0.36) | ALDH1A1MLYCDTSHRKDM4EMEN1 | |
| SCHEMBL4359169 | 0.73 | TARBP2 (0.40) | ALDH1A1TSHRKDM4EMEN1MAPT | |
| SCHEMBL29044483 | 0.73 | ALDH1A1 (0.39) | HTR2CALDH1A1CACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3193603-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016040498-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-8143243-B2 | 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[3-(4-morpholinylcarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester; 7H-indolo[2,1-a][2]benzazepine-10-carboxylic acid, 13-cyclohexyl-3-methoxy-6-[2-(4-morpholinylcarbonyl)phenyl]-, 1,1-dimethylethyl ester | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2396329-A1 | Compounds for the treatment of hepatitis c | Bristol-Myers Squibb Company (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20090275561-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | SMYD3, SMYD2, SNRPD3 | HTR2C 1075/4885ALDH1A1 1259/4885CACNA1F 2697/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | HTR2C 1075/4885ALDH1A1 1259/4885CACNA1F 2697/4885 |
| US-20090275561-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | HTR2C 3167/4885ALDH1A1 163/4885CACNA1F 4845/4885 |
| US-20200148650-A1 | ISOXAZOLE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SNRPD3 | HTR2C 1119/4885ALDH1A1 1132/4885CACNA1F 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.